Loading, Please Wait...
SCOTTSDALE, Ariz., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Item 9 Labs Corp. (OTC: INLB) (Item 9 Labs or the Company), a leading developer and manufacturer of innovative cannabis products and proprietary delivery platforms, today announced it received top honors at Arizona’s 2019 ERRL Cup Awards for the second consecutive year. The Company’s Candyland and Tres Leches cannabis flower strains were named 1st Place Sativa and 2nd Place Hybrid respectively.
Candyland previously received 1st Place Sativa honors at the 2018 ERRL Cup and the Company’s Vanilla Bean strain was named 1st Place Indica. Now in its fifth year, the ERRL Cup is an annual festival and awards event created to help patients receive safe access to clean and consistent medicine in Arizona.
“Out of 552 entries, it is an honor for Item 9 Labs to be recognized again. These ERRL Cup awards are a testament to our consistency and confirms our Company’s dedication to developing high-quality products with patient safety in mind,” stated Sara Gullickson, CEO of Item 9 Labs Corps.
The ERRL Cup is considered the “Patient’s Cup” because it is a third-party facilitated blind-tested judging process. In addition to ensuring credibility, the ERRL Cup also uses cannabinoid, pesticides, mold, growth regulators, terpenes, and residual solvent testing on every submission to gauge quality.
Item 9 Labs is headquartered in southern Arizona where it owns and operates one of the largest properties in the U.S. zoned to grow and cultivate medical cannabis covering 50 acres. Along with its flower and concentrates offerings, the Company is diversifying its product lines with proprietary THC and CBD-derived delivery systems, including its Intra-Nasal device and Apollo Vape Pen and Pod System.
For information visit Item9LabsCorp.com.
About Item 9 Labs Corp.:
Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today’s modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Item 9 Labs Corp.